From the Department of Neurology (H.H.Z.-F., C.V.S., E.S., J.I., E.F.W., S.J.P., J.J.C., B.G.W., D.D., J.-M.T., M.T., E.P.F.), Department of Laboratory Medicine and Pathology (S.J.P., D.D., E.P.F.), Department of Ophthalmology (J.J.C.), and Division of Pulmonary and Critical Care Medicine (H.Y.), Mayo Clinic, Rochester, MN; Department of Neurology (D.M.W.), Mayo Clinic, Scottsdale, AZ; and Department of Neurology (S.L.-C.), Mayo Clinic, Jacksonville, FL.
Neurology. 2021 Sep 28;97(13):e1351-e1358. doi: 10.1212/WNL.0000000000012599. Epub 2021 Aug 13.
Severe attacks of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory support, but data on episodes are limited, particularly for MOGAD. We sought to compare the frequency, characteristics, and outcomes of MOGAD and AQP4-NMOSD attacks requiring ventilatory support.
This retrospective descriptive study identified Mayo Clinic patients (January 1, 1996-December 1, 2020) with MOGAD or AQP4-NMOSD and an attack requiring noninvasive or invasive ventilation at Mayo Clinic or an outside facility by searching for relevant terms in their electronic medical record. Inclusion criteria were (1) attack-related requirement for noninvasive (bilevel positive airway pressure or continuous positive airway pressure) or invasive respiratory support (mechanical ventilation); (2) MOG or AQP4 antibody positivity with fulfillment of MOGAD and AQP4-NMOSD clinical diagnostic criteria, respectively; and (3) sufficient clinical details. We collected data on demographics, comorbid conditions, indication for and duration of respiratory support, MRI findings, treatments, and outcomes. The races of those with attacks requiring respiratory support were compared to those without such attacks in MOGAD and AQP4-NMOSD.
Attacks requiring ventilatory support were similarly rare in patients with MOGAD (8 of 279, 2.9%) and AQP4-NMOSD (11 of 503 [2.2%]) ( = 0.63). The age at attack (median years [range]) (MOGAD 31.5 [5-47] vs AQP4-NMOSD 43 [14-65]; = 0.01) and percentage of female sex (MOGAD 3 of 8 [38%] vs AQP4-NMOSD 10 of 11 [91%]; = 0.04) differed. The reasons for ventilation differed between MOGAD (inability to protect airway from seizure, encephalitis or encephalomyelitis with attacks of acute disseminated encephalomyelitis 5 [62.5%] or unilateral cortical encephalitis 3 [37.5%]) and AQP4-NMOSD (inability to protect airway from cervical myelitis 9 [82%], rhombencephalitis 1 [9%], or combinations of both 1 [9%]). Median ventilation duration for MOGAD was 2 days (range 1-7 days) vs 19 days (range 6-330 days) for AQP4-NMOSD ( = 0.01). All patients with MOGAD recovered, but 2 of 11 (18%) patients with AQP4-NMOSD died of the attack. For AQP4-NMOSD, Black race was overrepresented for attacks requiring ventilatory support vs those without these episodes (5 of 11 [45%] vs 88 of 457 [19%]; = 0.045).
Ventilatory support is rarely required for MOGAD and AQP4-NMOSD attacks, and the indications differ. Compared to MOGAD, these attacks in AQP4-NMOSD may have higher morbidity and mortality, and those of Black race were more predisposed, which we suspect may relate to socially mediated health inequality.
严重的髓鞘少突胶质细胞糖蛋白(MOG)抗体相关性疾病(MOGAD)和水通道蛋白-4(AQP4)抗体阳性视神经脊髓炎谱系疾病(AQP4-NMOSD)可能需要通气支持,但发作的数据有限,尤其是对于 MOGAD。我们旨在比较需要通气支持的 MOGAD 和 AQP4-NMOSD 发作的频率、特征和结局。
本回顾性描述性研究通过在电子病历中搜索相关术语,确定了梅奥诊所(1996 年 1 月 1 日至 2020 年 12 月 1 日)的 MOGAD 或 AQP4-NMOSD 患者,并在外院的梅奥诊所或其他医疗机构因发作而需要无创或有创通气。纳入标准为:(1)与发作相关的需要无创(双水平气道正压通气或持续气道正压通气)或有创呼吸支持(机械通气);(2)MOG 或 AQP4 抗体阳性,分别符合 MOGAD 和 AQP4-NMOSD 的临床诊断标准;(3)有足够的临床详细信息。我们收集了人口统计学、合并症、呼吸支持的适应证和持续时间、MRI 发现、治疗和结局等数据。比较了需要呼吸支持的发作患者与 MOGAD 和 AQP4-NMOSD 中无此类发作的患者的种族差异。
MOGAD(279 例患者中的 8 例,2.9%)和 AQP4-NMOSD(503 例患者中的 11 例,2.2%)中需要通气支持的发作同样罕见( = 0.63)。发作时的年龄(中位数[范围])(MOGAD 31.5 [5-47] 岁 vs AQP4-NMOSD 43 [14-65] 岁; = 0.01)和女性比例(MOGAD 8 例中的 3 例[38%] vs AQP4-NMOSD 11 例中的 10 例[91%]; = 0.04)不同。MOGAD 通气的原因(癫痫发作、脑炎或脑炎脊髓炎发作时无法保护气道 5 例[62.5%]或单侧皮质脑炎 3 例[37.5%])和 AQP4-NMOSD(无法保护气道免受颈髓炎 9 例[82%]、延髓炎 1 例[9%]或两者组合 1 例[9%])不同。MOGAD 的中位通气时间为 2 天(范围 1-7 天),而 AQP4-NMOSD 为 19 天(范围 6-330 天)( = 0.01)。所有 MOGAD 患者均康复,但 AQP4-NMOSD 患者中有 2 例(18%)死于发作。对于 AQP4-NMOSD,需要通气支持的发作黑人患者比例高于无此类发作的患者(11 例中的 5 例[45%] vs 457 例中的 88 例[19%]; = 0.045)。
MOGAD 和 AQP4-NMOSD 发作很少需要通气支持,而且适应证不同。与 MOGAD 相比,AQP4-NMOSD 发作的发病率和死亡率可能更高,而且黑人种族更容易发病,我们怀疑这可能与社会介导的健康不平等有关。